refractory plasma cell myeloma
Showing 26 - 50 of 80
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Adavosertib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +2 more
-
Portland, OregonOHSU Knight Cancer Institute
Jun 14, 2022
Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (biological, drug, other)
Recruiting
- Plasma Cell Myeloma
- +2 more
- Belantamab Mafodotin
- +4 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 10, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Jun 3, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Chemosensitivity Assay,
Terminated
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Carfilzomib
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
May 6, 2022
Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,
Active, not recruiting
- Refractory Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
- ixazomib citrate
- +2 more
-
Scottsdale, Arizona
- +4 more
Mar 28, 2022
Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)
Not yet recruiting
- Multiple Myeloma
- +4 more
- Pembrolizumab
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 23, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Ibrutinib, Laboratory
Suspended
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +5 more
-
Jacksonville, FloridaMayo Clinic in Florida
Mar 22, 2022
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia Trial in Duarte (drug,
Active, not recruiting
- Autologous Hematopoietic Stem Cell Transplant Recipient
- +4 more
- bortezomib
- +7 more
-
Duarte, CaliforniaCity of Hope
Mar 17, 2022
ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma Trial in Atlanta
Active, not recruiting
- ISS Stage I Plasma Cell Myeloma
- +4 more
- Pembrolizumab
- Radiation Therapy
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Mar 2, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +3 more
-
Calgary, Alberta, Canada
- +4 more
Feb 10, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Taselisib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Feb 4, 2022
Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia Trial in
Recruiting
- Myelodysplastic Syndrome
- +16 more
- Computed Tomography
- +6 more
-
Scottsdale, Arizona
- +2 more
Feb 3, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Dexamethasone, Leflunomide, Pomalidomide)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 10, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Nov 30, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Laboratory Biomarker Analysis, Lenalidomide,
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +2 more
-
Rochester, MinnesotaMayo Clinic
Dec 1, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (CS1-CAR T Therapy, Cyclophosphamide, Fludarabine)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- CS1-CAR T Therapy
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 15, 2021
Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Elotuzumab, Pomalidomide)
Suspended
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Jacksonville, FloridaMayo Clinic in Florida
Oct 18, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Laboratory Biomarker Analysis, Leflunomide,
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 4, 2021
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (drug,
Terminated
- Multiple Myeloma-Light Chain Only
- +2 more
- Dexamethasone
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor
Completed
- Advanced Lymphoma
- +5 more
- FGFR Inhibitor AZD4547
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 8, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Nivolumab)
Completed
- Advanced Lymphoma
- +5 more
- Nivolumab
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Mar 15, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (Bendamustine Hydrochloride, Carfilzomib,
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bendamustine Hydrochloride
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 7, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (Dexamethasone, Lenalidomide, Thalidomide)
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Dexamethasone
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2020